Article

Bilateral male breast cancer with male potential hypogonadism.

Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15, Kuramoto-Cho, Tokushima 770-8509, Japan.
World Journal of Surgical Oncology (Impact Factor: 1.2). 02/2007; 5:60. DOI: 10.1186/1477-7819-5-60
Source: PubMed

ABSTRACT Male breast cancer is a comparatively rare disease, and simultaneous bilateral male breast cancer is considered to be an extremely rare event. Risk factors are said to be genetic factors and hormonal abnormalities due to obesity or testicular diseases.
The patient was a 47-year-old Japanese male. His family had no history of female breast cancer. This patient also had hypospadias and hormonal examination indicated the presence of primary testicular potential hypogonadism, and these hormonal abnormalities seemed to be present since childhood or the fetal period. The bilateral breast cancer developed in this man at a comparatively young age, and histopathological studies of multiple sections showed that there was almost no normal epithelial cell in the ducts, while the ducts were almost completely filled with breast cancer cells.
It is thought that male breast cancer is caused by an imbalance between estrogen and testosterone. We cannot rule out the possibility that the breast cancer developed due to the effect of the slight elevation of estrogen over a long period of time, but the actual causative factors in this patient were unable to be definitively identified. In the future, we hope to further elucidate the causes of male breast cancer.

Full-text

Available from: Akira Tangoku, Mar 31, 2015
0 Bookmarks
 · 
98 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Male Breast Cancer (MBC) is a very rare neoplasm which accounts for 0.5- 1% of the total cases of breast cancer. Bilateral involvement is reported to occur in fewer than 2% of all the diagnosed cases of MBC, and synchronous tumors are very rare. Because of its rarity, little is known about MBC etiology, its clinical findings and treatment. Most patients present with a painless breast mass. The prognosis does not seem to be poor compared to that of the females, and it probably has a similar stage by stage prognosis. Surgical treatment is the gold standard for MBC. The authors report a case of simultaneous bilateral male breast cancer. The aim of this case report was to contribute to the available literature by this unusual presentation of the disease.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Synchronous bilateral breast cancer is extremely rare in men and has not, up to date, been reported in Korea. A 54-year-old man presented with a palpable mass in the right breast. The right nipple was retracted and bilateral axillary accessory breasts and nipples were present. On physical examination, a 2 cm-sized mass was palpated directly under the right nipple, and, with squeezing, bloody discharge developed in a single duct of the left nipple. There was no palpable mass in the left breast, and axillary lymph nodes were not palpable. Physical examination of external genitalia revealed a unilateral undescended testis on the left side. Synchronous bilateral breast cancer was diagnosed using mammography, ultrasonography, and core-needle biopsy. Histopathological examination revealed invasive ductal carcinoma in the right breast and ductal carcinoma in situ in the left breast. Bilateral total mastectomy, sentinel lymph node biopsy, and excision of accessory breasts in the axilla were performed.
    06/2012; 15(2):248-51. DOI:10.4048/jbc.2012.15.2.248
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The aim of this study was to investigate the clinicopathologic characteristics, therapy methods, and prognosis of male breast cancer. PATIENTS AND METHODS: We retrospectively analyzed the clinicopathological characteristics, recurrence or metastasis, and survival information of 87 male breast cancer patients. Statistical analysis included the Kaplan-Meier method to analyze survivals, log-rank to compare curves between groups, and Cox regression for multivariate prognostic analysis. A p value of <0.05 was considered statistically significant. RESULTS: 5-year disease free survival (DFS) and 5-year overall survival (OS) were 66.3 and 77.0%, respectively. Monofactorial analysis showed tumor size, stage, lymph node involvement, and adjuvant chemotherapy to be prognostic factors with regard to 5-year DFS and 5-year OS. Multivariate Cox regression analysis showed tumor size, stage, and adjuvant chemotherapy to be independent prognostic factors with regard to 5-year DFS and 5-year OS. CONCLUSION: Male breast cancer has a lower incidence rate and poor prognosis. Invasive ductal carcinoma is the main pathologic type. Operation-based combined therapy is the standard care for these patients. Tumor size, stage, and adjuvant chemotherapy are independent prognostic factors. More emphasis should be placed on early diagnosis and early therapy, and adjuvant chemotherapy may improve survival.
    Breast Care 12/2011; 6(6):446-451. DOI:10.1159/000335204 · 0.91 Impact Factor